Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Taskinen

Showing results (241-250 of 318) with videos related to

Pageof 32
Sort By:
Diabetes|November 1, 1986
Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapyM R Taskinen, W F Beltz, I Harper, et al.
Diabetologia|July 1, 1994
LDL subclasses in IDDM patients: relation to diabetic nephropathyS Lahdenperä, P H Groop, M Tilly-Kiesi, et al.
Diabetes|May 20, 1998
Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjectsR Malmström, C J Packard, M Caslake, et al.
European Journal of Clinical Investigation|June 11, 2003
Low HDL cholesterol concentration is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterolC Alagona, A Soro, J Westerbacka, et al.
Circulation|August 16, 2000
Endothelial dysfunction in men with small LDL particlesJ Vakkilainen, S Mäkimattila, A Seppälä-Lindroos, et al.
Atherosclerosis|June 28, 2001
Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatmentF Karpe, M R Taskinen, M S Nieminen, et al.
Diabetes Care|January 1, 1994
Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activityG Ruotolo, M Parlavecchia, M R Taskinen, et al.
Diabetologia|March 14, 1998
Effects of dietary cholesterol on plasma lipoproteins and their subclasses in IDDM patientsG Romano, M K Tilly-Kiesi, L Patti, et al.
International Journal of Clinical Practice|June 14, 2012
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensionR Gomis, D R Owens, M-R Taskinen, et al.
Atherosclerosis|February 13, 2001
Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL familiesK Ylitalo, V Large, P Pajukanta, et al.
Pageof 32

Showing results (241-250 of 318) with videos related to

Sort By:
Pageof 32
Diabetes|November 1, 1986
Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapyM R Taskinen, W F Beltz, I Harper, et al.
Diabetologia|July 1, 1994
LDL subclasses in IDDM patients: relation to diabetic nephropathyS Lahdenperä, P H Groop, M Tilly-Kiesi, et al.
Diabetes|May 20, 1998
Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjectsR Malmström, C J Packard, M Caslake, et al.
European Journal of Clinical Investigation|June 11, 2003
Low HDL cholesterol concentration is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterolC Alagona, A Soro, J Westerbacka, et al.
Circulation|August 16, 2000
Endothelial dysfunction in men with small LDL particlesJ Vakkilainen, S Mäkimattila, A Seppälä-Lindroos, et al.
Atherosclerosis|June 28, 2001
Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatmentF Karpe, M R Taskinen, M S Nieminen, et al.
Diabetes Care|January 1, 1994
Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activityG Ruotolo, M Parlavecchia, M R Taskinen, et al.
Diabetologia|March 14, 1998
Effects of dietary cholesterol on plasma lipoproteins and their subclasses in IDDM patientsG Romano, M K Tilly-Kiesi, L Patti, et al.
International Journal of Clinical Practice|June 14, 2012
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensionR Gomis, D R Owens, M-R Taskinen, et al.
Atherosclerosis|February 13, 2001
Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL familiesK Ylitalo, V Large, P Pajukanta, et al.
Pageof 32